The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shivalik Rasayan Ltd & PACs
MEDICAMEQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shivalik Rasayan Limited, the promoter of Medicamen Biotech, along with PAC Growel Remedies, has disclosed an acquisition under SEBI Takeover Regulations. The promoter group acquired 21,000 equity shares through the open market on March 21, 2025 and 5,00,000 fully convertible warrants on a preferential basis on April 24, 2025. After the acquisition, promoter holding stands at 54,87,095 shares (40.46% voting rights) plus 5,00,000 warrants (3.52% on a diluted basis), taking total to 42.12% on a diluted basis. Notably, the voting rights percentage dipped from 42.99% to 40.46% because the company's total equity capital expanded (from 1,27,14,600 to 1,35,62,815 shares) following the preferential allotment.
This signals promoter confidence and continued consolidation of control in Medicamen Biotech. With promoter holding rising on a diluted basis to 42.12% and moving closer to key takeover thresholds, investors should monitor further promoter acquisitions, as breaching the 50% or 5% creeping acquisition limits could trigger open offer obligations.